NASDAQ:NEXI NexImmune (NEXI) Stock Price, News & Analysis $0.21 -0.01 (-4.61%) (As of 11/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About NexImmune Stock (NASDAQ:NEXI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NexImmune alerts:Sign Up Key Stats Today's Range$0.21▼$0.2150-Day Range$0.20▼$0.8252-Week Range$0.20▼$28.69Volume884 shsAverage Volume846,679 shsMarket Capitalization$288,625.50P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Read More… Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Receive NEXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter. Email Address NEXI Stock News HeadlinesNexImmune (NASDAQ:NEXI) Shares Up 22.7% - Here's What HappenedOctober 29, 2024 | americanbankingnews.comShattuck Labs stock craters following pipeline and job cutsOctober 3, 2024 | msn.comMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.November 4, 2024 | Paradigm Press (Ad)NexImmune moves forward with wind-down processAugust 31, 2024 | bizjournals.comNexImmune adjourns special meeting to explore optionsAugust 4, 2024 | investing.comNEXI Stock Alert: NexImmune Delists From NasdaqJuly 12, 2024 | investorplace.comWhat Is Going on With NexImmune (NEXI) Stock Today?July 11, 2024 | investorplace.comNexImmune, Inc. Common Stock (NEXI) After-HoursMay 26, 2024 | nasdaq.comSee More Headlines NEXI Stock Analysis - Frequently Asked Questions How have NEXI shares performed this year? NexImmune's stock was trading at $2.22 at the start of the year. Since then, NEXI shares have decreased by 90.7% and is now trading at $0.2069. View the best growth stocks for 2024 here. How were NexImmune's earnings last quarter? NexImmune, Inc. (NASDAQ:NEXI) posted its earnings results on Wednesday, August, 7th. The company reported ($1.69) EPS for the quarter. When did NexImmune's stock split? NexImmune's stock reverse split before market open on Thursday, October 19th 2023. The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did NexImmune IPO? NexImmune (NEXI) raised $75 million in an initial public offering on Friday, February 12th 2021. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. served as the underwriters for the IPO. How do I buy shares of NexImmune? Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NexImmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that NexImmune investors own include Athenex (ATNX), Achilles Therapeutics (ACHL), TherapeuticsMD (TXMD), Bolt Biotherapeutics (BOLT), KLX Energy Services (KLXE), Lannett (LCI) and Exela Technologies (XELA). Company Calendar Last Earnings8/07/2024Today11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NEXI CUSIPN/A CIK1538210 Webwww.neximmune.com Phone301-825-9810FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($18.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-534.32% Return on Assets-213.72% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book0.06Miscellaneous Outstanding Shares1,395,000Free Float1,187,000Market Cap$288,625.50 OptionableNot Optionable Beta1.66 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:NEXI) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.